A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Type I Diabetes

Interventions

DRUG: Exenatide (Bydureon®)
DRUG: Placebo

Sponsor

Yale University